Skip to content

Assessment of Methamphetamine Craving and Detection of Blood Markers in Methamphetamine Addicts

Assessment of Methamphetamine Craving and Detection of Blood Markers in Methamphetamine Addicts

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112259
Enrollment
Unknown
Registered
2025-11-12
Start date
2025-11-30
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine use disorder

Interventions

Sponsors

Jiangsu Province Official Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Eligibility criteria for participants in the health study: Healthy adult men and non-lactating women who are not pregnant, aged between 20 and 50 years old, with men weighing at least 50kg and women weighing at least 45kg. (2) Good health, with no history of liver, kidney, digestive tract, nervous system, mental disorders or metabolic diseases; There is no history of other chronic diseases. (3) Before the trial, sign the informed consent form, fully understand the content, process and possible adverse reactions of the trial, and be able to communicate well with the researcher. 2. Eligibility criteria for participants in the methamphetamine addiction study: Participants who inhaled methamphetamine with a net content of 100mg to 120mg within 7 days (ensuring the validity of the sample), aged between 20 and 50 years old, with a male weight of at least 50kg and a female weight of at least 45kg. (2) Be diagnosed in relevant drug rehabilitation units as meeting the substance addiction diagnostic criteria in DSM-V (Diagnostic and Statistical Manual of Mental Disorders: Substance Related and Addiction Disorders), and complete the compliance physical examination at the same time. Has detailed medical records, and has a history of heart, liver, kidney, digestive tract, nervous system, mental abnormalities and metabolic diseases. There is no history of other chronic diseases. (3) Before the trial, sign the informed consent form, fully understand the content, process and possible adverse reactions of the trial, and be able to communicate well with the researcher.

Exclusion criteria

Exclusion criteria: 1. Surgery is planned within approximately six months in the near future. 2. People with a specific history of allergies (such as asthma, measles, eczema, etc.), or those with allergic constitutions (such as those allergic to two or more drugs, foods, and pollen); 3. Those who have plans to have children in the near future (within 6 months) and are unwilling to accept contraceptive measures during the study period; 4. Participants in the health study have a history of psychotropic substance abuse; Participants in the methamphetamine addiction study had a history of abuse of psychotropic drugs other than methamphetamine. 5. Positive for human immunodeficiency virus antibody (HIV-Ab), hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), or Treponema pallidum antibody (RPR); 6. Previous experience of fainting at the sight of blood or needles, or difficulty in blood collection; 7. Research participants may be unable to complete this study for other reasons or may be deemed unsuitable to participate in this study by the researchers.

Design outcomes

Primary

MeasureTime frame
Circular RNA;Craving Assessment Scale score;Lactic acid;

Countries

China

Contacts

Public ContactBo Gui

Jiangsu Province Official Hospital

guibosy@njmu.edu.cn+86 25 8969 9049

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026